Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of emibetuzumab (LY2875358) in MET-positive advanced gastric or gastroesophageal junction cancer
jRCT2080222178Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of emibetuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Aug 2013; status: completed.
02
Drugs
emibetuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222178.